Skip to content

CapEx at other companies

Biogen logo
BiogenBIIB
$51.2M+38.0%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$9.1M-15.0%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$27K
PTC Therapeutics logo
PTC TherapeuticsPTCT
$1.2M-30.6%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$69K
TG Therapeutics logo
TG TherapeuticsTGTX
$51K+104%

Other financials

Income statement

See full
Revenue$268.1M+9.7%
Gross profit$243.3M+8.6%
Operating income-$4.6M-124%
Net income$3.6M-80.8%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$282.2M+29.6%
Total debt$50.8M-9.3%
Total equity$1.2B+63.1%
Total assets$1.6B+41.8%

Cash flow

See full
Operating cash flow$34.0M+67.2%
Free cash flow$28.8M+41.6%

Valuation

See full
Market cap$3.7B+37.0%
Enterprise value$3.47B+36.6%
P/E9.9×-2.0×
P/S3.4×+0.7×

Profitability

See full
Gross margin91.5%-0.6pp
Operating margin7.4%-16.2pp
Net margin34.3%+11.3pp
FCF margin18.9%

Returns & leverage

See full
Return on equity37.3%+0.1pp
Debt / equity0.0×
Current ratio3.6×+0.7×

Where this comes from

Reported directly by Acadia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Acadia Pharmaceuticals's capex.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Acadia Pharmaceuticals's capex?
Acadia Pharmaceuticals (ACAD) reported capex of $5.21M in Q1 2026.
What is the long-term trend for Acadia Pharmaceuticals's capex?
Over 3 years (2021 to 2025), Acadia Pharmaceuticals's capex has grown at a 61.1% compound annual growth rate (CAGR), from $1.12M to $4.69M.
What does capex mean?
Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.